Prevention of Chemotherapy-Induced Cardiotoxicity in High-Risk Patients

This study has been completed.
Sponsor:
Information provided by:
European Institute of Oncology
ClinicalTrials.gov Identifier:
NCT00292526
First received: February 15, 2006
Last updated: NA
Last verified: January 2006
History: No changes posted
  Purpose

In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.


Condition Intervention Phase
Chemotherapy-Induced Cardiotoxicity Revealed by TnI Increase.
Drug: oral enalapril
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by European Institute of Oncology:

Primary Outcome Measures:
  • Incidence of chemotherapy-induced cardiotoxicity

Secondary Outcome Measures:
  • Major adverse cardiac events, including death.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I

Exclusion Criteria:

  • Contraindication to ACE-inhibitors
  • On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00292526

Locations
Italy
European Institute of Oncology
Milan, Italy, 20141
Sponsors and Collaborators
European Institute of Oncology
Investigators
Study Director: Carlo M Cipolla, MD European Institute of Oncology
Principal Investigator: Daniela Cardinale, MD European Institute of Oncology
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00292526     History of Changes
Other Study ID Numbers: IEO S67/500
Study First Received: February 15, 2006
Last Updated: February 15, 2006
Health Authority: Italy: Ministry of Health

Keywords provided by European Institute of Oncology:
Chemotherapy-induced cardiotoxicity
Troponin
Heart failure

Additional relevant MeSH terms:
Enalapril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 22, 2014